In today’s world, there is much to be admired in someone who refuses to make a profit out of a good idea for the greater good. David Edquilang invented a new type of finger prosthesis called Lunet that has earned him awards around the world but he plans on making the design open access to benefit those who need it most.
Helping the greatest number of people
“Not every good idea needs to be turned into a business. Sometimes, the best ideas just need to be put out there,” said Edquilang in a statement issued by his university. “Medical insurance will often not cover the cost of a finger prosthesis, since it is not considered vital enough compared to an arm or leg. Making Lunet available online for free will allow it to help the greatest number of people.”
Actor Suzanne Somers has died at the age of 76 after being diagnosed with breast cancer more than two decades ago, which ultimately was her cause of death.
Somers was best known for her roles in the hit sitcoms “Three’s Company” and “Step by Step,” and later in life for her health and fitness business ventures.
Somers died “peacefully at home” surrounded by her family on Oct. 15, one day before her 77th birthday, according to a statement to NBC News from Somers’ publicist on behalf of her family.
Nanozymes are synthetic materials that mimic the properties of natural enzymes for applications in biomedicine and chemical engineering. Historically, they are generally considered too toxic and expensive for use in agriculture and food science. Now, researchers from the University of Illinois Urbana-Champaign have developed a nanozyme that is organic, non-toxic, environmentally friendly, and cost effective.
In a newly published paper, they describe its features and its capacity to detect the presence of glyphosate, a common agricultural herbicide. Their goal is to eventually create an user-friendly test kit for consumers and agricultural producers.
“The word nanozyme is derived from nanomaterial and enzyme. Nanozymes were first developed about 15 years ago, when researchers found that iron oxide nanoparticles may perform catalytic activity similar to natural enzymes (peroxidase),” explained Dong Hoon Lee, a doctoral student in the Department of Agricultural and Biological Engineering (ABE), part of the College of Agricultural, Consumer and Environmental Sciences (ACES) and The Grainger College of Engineering at U. of I.
If you want optimism about life extension, here is Bill Faloon at RAADFest with the latest.
Bill Faloon gave the keynote presentation at the RAADfest conference in September 2023. In his talk, he discussed many of the advances in longevity research over the past year and described the main barrier to faster advances in regenerative medicine.
Karin’s life took a dramatic turn when a farming accident claimed her right arm more than 20 years ago. Since then, she has endured excruciating phantom limb pain. “It felt like I constantly had my hand in a meat grinder, which created a high level of stress and I had to take high doses of various painkillers.”
In addition to her intractable pain, she found that conventional prostheses were uncomfortable and unreliable, and thus of little help in daily life. All this changed when she received groundbreaking bionic technology that allowed her to wear a much more functional prosthesis comfortably all day. The higher integration between the bionics and Karin’s residual limb also relieved her pain. “For me, this research has meant a lot, as it has given me a better life.”
Mechanical attachment and reliable control are two of the biggest challenges in artificial limb replacement. People with limb loss often reject even the sophisticated prostheses commercially available due to these reasons, after experiencing painful and uncomfortable attachment with limited and unreliable controllability.
Automation and sector-wide collaboration will be critical as developers try to move beyond the production challenges that slow growth of the cell and gene therapy sector. So says Julie G. Allickson, PhD, director of Mayo Clinic’s Center for Regenerative Biotherapeutics who argues that, despite considerable investment in infrastructure, production is still the biggest challenge.
“Both industry and academia are challenged by the lack of manufacturing capacity for cell and gene therapies,” she says, citing plasmid production and viral vector production as examples. “Besides these issues, the scalability of production processes can be difficult, especially when coupled to individually expanded cells. When looking at the patient cells variability, quantity and quality of cells is critical to ensure consistency in the product delivered to the patient,” she says.
Michael Levin, a developmental biologist at Tufts University, challenges conventional notions of intelligence, arguing that it is inherently collective rather than individual.
Levin explains that we are collections of cells, with each cell possessing competencies developed from their evolution from unicellular organisms. This forms a multi-scale competency architecture, where each level, from cells to tissues to organs, is solving problems within their unique spaces.
Levin emphasizes that properly recognizing intelligence, which spans different scales of existence, is vital for understanding life’s complexities. And this perspective suggests a radical shift in understanding ourselves and the world around us, acknowledging the cognitive abilities present at every level of our existence.
The Collective Intelligence of Cells During Morphogenesis: What Bioelectricity Outside the Brain Means for Understanding our Multiscale Nature with Michael Levin — Incredible Minds.
Recorded: April 29, 2023.
Each of us takes a remarkable journey from physics to mind: we start as a blob of chemicals in an unfertilized quiescent oocyte and becomes a complex, metacognitive human being. The continuous process of transformation and emergence that we see in developmental biology reminds us that we are true collective intelligences – composed of cells which used to be individual organisms themselves. In this talk, I will describe our work on understanding how the competencies of single cells are harnessed to solve problems in anatomical space, and how evolution pivoted this scaling of intelligence into the familiar forms of cognition in the nervous system. We will talk about diverse intelligence in novel embodiments, the scaling of the cognitive light cone of all beings, and the role of developmental bioelectricity as a cognitive glue and as the interface by which mind controls matter in the body. I will also show a new synthetic life form, and discuss what it means for bioengineering and ethics of human relationships to the wider world of possible beings. We will discuss the implications of these ideas for understanding evolution, and the applications we have developed in birth defects, cancer, and traumatic injury repair. By merging deep ideas from developmental biophysics, computer science, and cognitive science, we not only get a new perspective on fundamental questions of life and mind, but also new roadmaps in regenerative medicine, biorobotics, and AI.
Michael Levin received dual undergraduate degrees in computer science and biology, followed by a PhD in molecular genetics from Harvard. He did his post-doctoral training at Harvard Medical School, and started his independent lab in 2000. He is currently the Vannevar Bush chair at Tufts University, and an associate faculty member of the Wyss Institute at Harvard. He serves as the founding director of the Allen Discovery Center at Tufts. His lab uses a mix of developmental biophysics, computer science, and behavior science to understand the emergence of mind in unconventional embodiments at all scales, and to develop interventions in regenerative medicine and applications in synthetic bioengineering. They can be found at www.drmichaellevin.org/
Researchers map gene switches and brain cell types associated with schizophrenia, bipolar disorder, Alzheimer’s.
Alzheimer’s disease is a disease that attacks the brain, causing a decline in mental ability that worsens over time. It is the most common form of dementia and accounts for 60 to 80 percent of dementia cases. There is no current cure for Alzheimer’s disease, but there are medications that can help ease the symptoms.
According to a study recently presented at the European Respiratory Society International Congress in Milan, Italy, young people who have used e-cigarettes are more than twice as likely to report experiencing chronic stress.
The study was presented by Dr Teresa To, a senior scientist at The Hospital for Sick Children (SickKids) in Toronto, Canada. She said: “Research is starting to show how vaping affects young people’s physical and mental health. For example, our previous research has shown that those who vape are more likely to suffer an asthma attack. In this study, we were particularly interested in the relationship between vaping, mental health, and quality of life among young people.”
